Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



2 Reasons to Watch Amgen, Inc.

Amgen (NASDAQ: AMGN  ) is looking at two great opportunities. The company's brightest immune-oncology prospect is giving mixed results on its own, but a valuable partnership seems likely. In the race to produce a next-generation cholesterol reducer, high marks from a difficult to treat population put Amgen in the pole position. Let's take a closer look at what look like the two biggest opportunities facing Amgen.

When it works... it really works
Most of the excitement surrounding cancer immunotherapies has shifted from vaccines to more promising immune checkpoint regulators. Amgen isn't in the anti-PD-1 checkpoint race, but it may have a chance to share in the success with talimogene laherparepvec, or T-vec.

This virus replicates inside infected tumor cells until they burst, while attracting an immune response. Recently presented data at this year's American Society of Clinical Oncology meeting suggests it could be an important part of combination therapies.

In a mid-stage trial, advanced melanoma patients were given a combination of T-Vec and Yervoy from Bristol-Myers Squibb. Tumors either shrank in size or were no longer detectable in more than half of patients when T-vec was given prior to and in combination with Yervoy. Given the tolerability of the combo and the advanced state of disease treated, eliciting a response from any patients would be impressive, but more than half is just incredible.

Not only does T-Vec help elicit responses from advanced patients, those responses are often durable. Amgen also presented data from a separate late-stage trial with T-vec as a monotherapy. When the advanced melanoma patients responded to T-Vec, the chances of that response lasting 12 months or longer was 65%.

Amgen's cancer virus/vaccine really needed the image boost. A failure to significantly improve overall survival in the monotherapy trial overshadowed the impressive response data. On its own, T-Vec treatment helped patients show a trend toward increased survival, but just below what would be considered statistically significant.

Amgen investors will want to keep an eye open for survival data from upcoming combination studies. Luckily, Bristol-Myers isn't the only company lining up to try its new cancer therapies alongside the novel virus. Earlier this year Merck (NYSE: MRK  ) agreed to test its anti-PD1 therapy pembrolizumab -- the antibody formerly known as MK-3475 -- with T-Vec in a phase 1-2 study with untreated advanced melanoma patients.

Last month the FDA accepted Merck's application for pembrolizumab to treat advanced melanoma. The company is expecting a response from the FDA in late October. If approved, it could help clear a path for a possible combination with T-Vec in the future.

Statin-less cholesterol control
Amgen's positives for the week didn't stop at oncology. The company scored another big win in the race to develop a next-generation low-density lipoprotein cholesterol, or LDL-C lowering drug. Evolocumab is an injectable antibody that inhibits PCSK9 -- a protein that regulates the liver's rate of LDL-C absorption.

Amgen is testing the new class of therapy in a wide range of patients, but the latest results come from perhaps the most difficult treatment profile. Homozygous familial hypercholesterolemia, or HoFH, is an extremely rare genetic condition marked by a lack of viable LDL-C receptors. Using evolocumab to slow reabsorption of the few receptors these patients do have, significantly reduced LDL-C.

The observed 31% LDL-C reduction from baseline could cause big trouble for Aegerion Pharmaceuticals (NASDAQ: AEGR  ) . Its only marketed product Juxtapid is approved solely for the treatment of HoFH patients. While Juxtapid will likely remain necessary for most of the population, these results suggest Aegerion could lose in the years ahead. Amgen hasn't priced its PCSK9 therapy, but I think we can assume it will be far below Juxtapid's $300,000 per year. Given the extremely limited number of HoFH patients, every patient that opts for evoculamab over Juxtapid is going to sting.

Final thoughts
On the cholesterol front, evolucumab's efficacy within an extremely difficult patient population is highly encouraging. The HoFH population is limited, but the results put Amgen another step ahead of competitors racing to develop a PCSK9 inhibitor.

Not long ago, Amgen's lack of late-stage anti-PD1 candidates was a concern for its overall oncology program. T-Vec's improved chance of becoming part of at least one anti-PD-1 combination therapy could give the company a much needed boost.

Warren Buffett just bought nearly 9 million shares of this company
Imagine a company that rents a very specific and valuable piece of machinery for $41,000 per hour (That's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock... and join Buffett in his quest for a veritable landslide of profits!

Read/Post Comments (0) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2982305, ~/Articles/ArticleHandler.aspx, 9/4/2015 9:14:23 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Cory Renauer

Cory is a long-term minded analyst mainly focused on the biotechnology and pharmaceuticals. He genuinely enjoys cutting through the industry's complexities to help everyday investors make better decisions. You can contact Cory on Twitter @coryrenauer

Today's Market

updated Moments ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 3:59 PM
AEGR $17.70 Down -0.06 -0.34%
Aegerion Pharmaceu… CAPS Rating: **
AMGN $147.02 Down -2.21 -1.48%
Amgen CAPS Rating: ****
MRK $51.59 Down -1.06 -2.01%
Merck & Co., Inc. CAPS Rating: ****